

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Medical technologies evaluation programme

Equality impact assessment: Topic selection and scoping

MT562 FibroScan for assessing liver fibrosis and cirrhosis outside secondary and specialist care

The impact on equality has been assessed during this evaluation according to the principles of the [NICE Equality scheme](#).

1. Have any potential equality issues been identified during the development of the topic briefing note or during selection, and, if so, what are they?

No equality issues were identified during the scoping process. The equality considerations identified are that

- The device failure rates may be higher in people with high BMI, particularly for people with central obesity.
- The risk of liver disease may be higher in people who abuse alcohol and hazardous substances and people from ethnic groups (Black African, African Caribbean and South Asian) with a higher risk of developing type 2 diabetes
- Liver cirrhosis may in the long term, prevent a person from performing their normal day-to-day activities. Disability is a protected characteristic under the Equality Act 2010.

2. What is the preliminary view as to what extent these potential equality issues need addressing by the committee?

Test failure has been added as an outcome. If evidence is available, the committee will consider this outcome.

3. Has any change to the draft scope been agreed to highlight potential equality issues?

The equality considerations identified have been added to the decision problem table in the scope and test failure was added as an outcome.

4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the stakeholder list been made?

No

Approved by Associate Director: Rebecca Albrow

Date: 3 September 2021